General Updates

07th July 2026 The BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, “Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Bandra (E) Mumbai – 400001 Mumbai - 400051 Scrip Code: 517556 Symbol: PVP Debt-18PVL29A, 18PVL29 Dear Sir/Madam, Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of Further Acquisition of Stake in 7 Med India Private Limited In continuation of our earlier intimations dated 28th August 2025 and 4th November 2025 regarding the acquisition of an equity stake in 7 Med India Private Limited, we wish to inform you that the company has successfully completed the acquisition of an additional 4,263 equity shares of 7 Med India Private Limited. Pursuant to the aforesaid acquisition, the company’s shareholding in 7 Med India Private Limited has increased to 41.23% of the total paid-up share capital of the target company. This acquisition has been completed in accordance with the terms of the Share Purchase Agreement and the Shareholders’ Agreement executed between the parties, and forms part of the company’s strategic investment in the healthcare sector. The company remains committed to completing the balance acquisition in terms of the definitive agreements executed between the parties. The brief details, as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, are enclosed herewith as Annexure A. Request you to kindly take the same on record. For PVP Ventures Limited Prasad V Potluri Chairman & Managing Director Attached: As in above Annexure A Details required to be provided while disclosing an event under Regulation 30, Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024: S.NO PARTICULARS DETAILS 1 Name of the target entity, details in 7Med India Pvt. Ltd. brief such as size, turnover etc.; 7Med India Pvt Ltd is among the top five organized players in India’s renal care sector, offering a comprehensive range of dialysis services across its pan-India network. 2 Whether the acquisition would fall The acquisition does not fall within the within related party transaction(s) and ambit of a related party transaction. It has whether the promoter/ promoter been undertaken in accordance with the group/ group companies have any transaction documents executed by the interest in the entity being acquired? If Company, including the Share Purchase yes, nature of interest and details Agreement and Shareholders’ Agreement, thereof and whether the same is done and is on an arm’s length basis. This at “arm’s length”; acquisition represents the second tranche of the transaction, the first tranche having been completed on 4th November 2025, pursuant to which 7 Med India Private Limited became an associate company of the Company. Other than the shareholding disclosed above, none of the promoter/promoter group/group companies have any interest in the entity being acquired. 3 Industry to which the entity being Healthcare acquired belongs; 4 Objects and impact of acquisition The acquisition is in furtherance of the (including but not limited to, disclosure company’s strategic expansion into the of reasons for acquisition of target healthcare sector. entity, if its business is outside the main line of business of the listed entity) 5 Brief details of any governmental or Nil regulatory approvals required for the acquisition; 6 Indicative time period for completion The acquisition of the additional 4,263 of the acquisition; equity shares, taking the Company’s shareholding to 41.23%, has been completed. The balance shareholding, to take the Company’s aggregate stake to 50.62%, is expected to be completed in accordance with the terms of the definitive agreements executed between the parties. 7 Consideration -whether cash Cash consideration. consideration or share swap or any other form and details of the same; 8 Cost of acquisition and/or the price at The transaction shall be a combination of which the shares are acquired both primary and secondary stake purchase amounting to an outlay of circa INR 127 crores for this majority shareholding (50.62%). 9 Percentage of shareholding / control Acquisition of 4,263 equity shares resulting acquired and / or number of shares in an increase in shareholding to 41.23% of acquired the paid-up share capital of 7 Med India Private Limited. 10 Brief background about the entity 7Med India Pvt Ltd is among the top five acquired in terms of products/line of organized players in India’s renal care business acquired, date of sector, offering a comprehensive range of incorporation, history of last 3 years dialysis services across its pan-India turnover, country in which the acquired network. entity has presence and any other significant information (in brief); For PVP Ventures Limited Prasad V Potluri Chairman & Managing Director